Geneeda Biotech Secures Series A Strategic Financing Led by Sinochem Capital Ventures and BGI Harvest Fund

Recently, Zhongjin Haihe Fund, under Sinochem Capital Venture Capital, together with Changzhou Huada Songhe Fund, jointly completed a Series A strategic investment in Jiinda Biotechnology (Ningbo) Co., Ltd. (“Jiinda”). Maibo Capital served as the exclusive financial advisor. The proceeds from this financing round will accelerate the development of Jiinda’s synthetic biology platform product pipeline in high-value-added food, health supplement, and feed ingredient sectors, scale up commercial production, expand application scenarios, and facilitate market expansion both domestically and internationally.

Compared with the traditional chemical industry, synthetic biology offers advantages in cost-effectiveness and sustainability. It demonstrates significant strengths in producing specialized and complex products, such as natural compounds, while gradually becoming competitive in the realm of low-carbon small-molecule chemicals. In recent years, synthetic biology has entered a fast lane for industrial development. Currently, breakthroughs have been achieved in foundational technologies such as gene sequencing, synthesis, and editing, which show strong potential for cost control. The inflection point for industry growth has arrived, paving the way for rapid technological iteration and advancement.

Founded in 2021, JiYinDa Bio is dedicated to the development and commercialization of innovative synthetic biology technologies to enable sustainable, cost-effective, and environmentally friendly production of high-value chemicals. The company boasts a world-leading synthetic biology technology platform, with innovation-driven R&D at its core. It has established a diverse product portfolio, with its flagship product having obtained certifications including approval from the U.S. FDA, while multiple other products are progressing smoothly through development.

The company’s core team has been deeply engaged in the field of synthetic biology for many years, possessing world-class R&D backgrounds and mature commercialization experience. The team includes several leading scholars in the field of synthetic biology, with publications in top-tier journals includingNature Biotechnology, Nature Communications, PNASPublished over 100 articles in journals and magazines, with extensive experience in the commercialization of multiple technical patents.

Leveraging its synthetic biology technology platform, Jiyinda has developed and is currently developing a series of high-value-added compound products with significant market opportunities. These initiatives align with the strategic direction of fostering high-quality development in the animal nutrition supply chain and achieving source-level carbon reduction, thereby offering substantial potential for synergistic collaboration with investors’ existing value chains in animal nutrition and related sectors.

Sinochem Chuangke Team stated:Jiyinda’s core team has been deeply engaged in the field of synthetic biology for over 20 years, possessing the capability to rapidly construct high-efficiency microbial strains. With extensive experience in fermentation optimization and scaled-up production, the company selects products with high added value and relatively large market sizes, effectively addressing key market pain points for each product. With clear strategic positioning, Jiyinda is a highly promising synthetic biology enterprise.

The Changzhou BGI Songhe Fund team stated:Geneada brings together top synthetic biology scientists from China and the United States, having completed numerous pioneering works in the field of metabolic engineering. Its distinctive technology platform covers multiple downstream sectors, featuring unique product selection insights and the ability to rapidly develop and iterate products according to market demands. BGI Group closely monitors the development of synthetic biology and has already established a presence in upstream areas such as DNA synthesis and reagent raw materials. It seeks to collaborate with Geneada to explore and expand into downstream application markets.

Sinochem Capital Innovation Investment Co., Ltd. (hereinafter referred to as “Sinochem Capital VC”) serves as the unified management platform for Sinochem Holdings’ industrial fund business. By aggregating social capital, it strategically invests along Sinochem’s core industrial chain, collaborates to identify high-quality projects, and explores and nurtures emerging industries, thereby creating a second growth engine for Sinochem’s industrial innovation and upgrading. The company focuses on two key investment sectors: new chemical materials and modern agriculture, with entrusted assets under management totaling nearly RMB 15 billion.

The Changzhou Huada Songhe Venture Capital Fund was jointly established by Changzhou Venture Capital Group, Jintan Holdings, Songhe Capital, and BGI Group. The fund focuses on investments in biomedicine, new energy, new materials, and other sectors, covering projects at early-to-mid stages and pre-IPO phases, thereby facilitating the rapid development of Changzhou’s biomedical industry.

MedBio Capital is a boutique investment bank focused on the life sciences and healthcare sectors, dedicated to becoming the capital and strategic partner of top scientists and entrepreneurs. Its core team has deep expertise in the medical industry, covering key stages from R&D and clinical development to commercialization, and possesses composite backgrounds in investment, investment banking, and consulting. Team members have collectively facilitated over RMB 10 billion in financing and have served more than ten leading publicly listed healthcare companies.